Skip to content

Erasca, Inc. ERAS Retained Earnings

Retained Earnings at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$18.29B+13.5%
Eli Lilly logo
Eli LillyLLY
$29.51B+95.5%
Pfizer logo
PfizerPFE
$117.24B-2.0%
Amgen logo
AmgenAMGN
-$24.65B+9.2%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$3.32B-70.3%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$648.67M-19.8%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s retained earnings?
Erasca, Inc. (ERAS) reported retained earnings of -$1.08B in Q1 2026.
How has Erasca, Inc.'s retained earnings changed year-over-year?
Erasca, Inc.'s retained earnings decreased by 34.7% year-over-year, from -$798.63M to -$1.08B.
What is the long-term trend for Erasca, Inc.'s retained earnings?
Over 5 years (2020 to 2025), Erasca, Inc.'s retained earnings has grown at a 50.5% compound annual growth rate (CAGR), from -$115.4M to -$892.21M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.